Britto C, Cardoso A, Silveira C, Macedo V, Fernandes O
Department of Biochemistry and Molecular Biology, Instituto Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, Brasil.
Medicina (B Aires). 1999;59 Suppl 2:176-8.
The evaluation of the treatment for chronic Chagas disease faces the absence of any clear-cut criterion of cure. The low degree of parasitemia and the persistence of positive immunologic reactions represent some of the difficulties involved in addressing therapeutic efficacy. Our aim was to define whether PCR could be used as a laboratory method for evaluating cure in Chagas disease after specific treatment. We tested the utility of PCR amplification of the variable regions of minicircles from Trypanosoma cruzi kinetoplast DNA, in 76 xeno-positive chronic Brazilian patients who have been treated with benznidazole in Mambai (Goias State) and São Felipe (Bahia State). We observed a positive amplification result in only 25 out of 76 treated patients (33%). Therefore, the performance of one single PCR after therapy revealed parasite clearance in 67% of the treated individuals, while xenodiagnosis was negative in 84%. These observations suggest that PCR is the most sensitive technique available for direct detection of T. cruzi in chagasic patients and that it can be a very useful instrument for the follow-up of patients after specific chemotherapy. In this sense, we are now developing a quantitative approach based on the use of fluorogenic probes and real-time measurement of the amplification reaction (TaqMan technology) in order to precisely estimate the parasite load in chronic chagasic patients before and after treatment. This may be the basis for the future establishment of reliable criteria of cure for patients undergoing therapy.
慢性恰加斯病治疗效果的评估面临着缺乏明确治愈标准的问题。寄生虫血症程度低以及免疫反应持续呈阳性是评估治疗效果时所涉及的一些困难。我们的目的是确定PCR是否可作为一种实验室方法,用于评估恰加斯病经特定治疗后的治愈情况。我们检测了来自克氏锥虫动基体DNA微小环可变区的PCR扩增的效用,检测对象为76名在曼拜(戈亚斯州)和圣费利佩(巴伊亚州)接受过苯硝唑治疗的巴西慢性异嗜性抗体阳性患者。我们观察到,在76名接受治疗的患者中,只有25名(33%)获得了阳性扩增结果。因此,治疗后单次PCR检测显示,67%的治疗个体体内的寄生虫被清除,而异体诊断的阴性率为84%。这些观察结果表明,PCR是检测恰加斯病患者体内克氏锥虫最敏感的技术,并且它可以作为特定化疗后患者随访的非常有用的工具。从这个意义上说,我们目前正在开发一种基于荧光探针使用和扩增反应实时测量(TaqMan技术)的定量方法,以便精确估计慢性恰加斯病患者治疗前后的寄生虫载量。这可能是未来为接受治疗的患者建立可靠治愈标准的基础。